med-tech valuat continu soar devic index trade
premium market price-to-earnings basi pg observ less
calls/concern result might trend though notic
focu simpli beat discuss valuat
level feel mani need beat maintain current valuat one
concern euro declin possibl lead guidanc revis
like steadi guidanc even beat large-cap discuss
providers/doc point toward steadi procedur though slightli
week shift late march may help year optic
neutral quarterli trade go print
feel guidanc conserv continu insur win
market cushion result think set guidanc
level miss anoth product revenu beat like
may get price off-set libr
price dynam yet dont think post sizeabl top
line beat lastli consist beaten number
littl risk ou last quarter go direct
possibl distributor mayb oversel bit number could
come strong one risk though ou channel could bit
full management might talk
nervou buy pt neutral
see cynosur improv model street fear
weak result could lead share pullback run north
consist miss quarter limit
confid number half year done management
good view evalu thu may need revis guidanc lower
littl room error call
compani miss valuat neutral ew neutral
neutral neutral neutral leav
room result come light
rais price target buy pt buy pt
increas pt feel consist
result combin possibl lotu return support case
sustain price-to-earnings multipl adjust model
less dilut post redempt ge rate prefer share
pleas read import disclosur analyst certif appear appendix
tabl content
rel valuat multipl devic vs
preview forecast revenu adj ep bit
lower consensu revenu in-lin ep given compani
reiter forward-look guidanc midway report period
analyst day think less like major surpris
accompani print notabl benefit easier
y/i comp organ growth first half vs
second half though expect util slow sequenti
strong flu season see much risk achiev underli growth
howev euro also weaken intra-quart expect
downward pressur report number think stock share
nice run sinc earli may partial new execut hire
feel less like move in-lin quarter
segment anticip continu strength diabet easier
comparison on-going demand minim ou
strength addit pain portfolio trend better
expect wonder intelli taken share player
like rate cvg group face tough
comp given time product cycl optic could bit soft
segment
share ntm price-to-earnings valuat compel lower
peer group feel inconsist oper margin perform mix
unexpect surpris mayb lack transpar less meaning
growth driver robot launch delay make difficult argu multipl
expans near-term
quarterli call expect discuss launch guardian connect
cgm updat minim follow receipt ce mark
new pediatr indic await color new product rollout
neurovascular side aspir cathet anticip also hot
topic potenti spur intra-quart headlin med-tech
player analyst day held month ago expect littl
chang term strategi
select categori forecast heart failur con
cardiac vascular group con minim
invas group legaci covidien con spine
con restor therapi group con
diabet con
model chang recalcul currenc model reflect weaker
euro addit adjust mitg estim restat prior year
ago quarter patient monitor recoveri divestitur altogeth
result reduct out-year estim littl sens
margin fare assum success offset expens
keep ep forecast steadi
valuat rate neutral next twelv month price-to-earnings
basi share trade estim discount
large-cap med-tech peer group howev feel current valuat
warrant given slower growth vs group inconsist around
revenu oper margin perform btig provid price
target neutral-r stock risk includ guidanc oper
margin expans underli pressur spine market soft
emerg market margin degrad expans new busi
line competit slippag product timelin chang procedur
reimburs futur devic data fda use cash/m
growth net btig estim compani filingsnewold changentm johnsonjnjsel bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap
medtron incom eproduct net y/i good gross total oper expens adj oper interest expens pre-tax incom adj net non-controlling adj net incom adjust ep share total net ex select calendar net oper ep oper net product product product oper btig estim compani report
medtron revenu ecrm heart failur structur heart y/i peripher vascular total recast y/i vascular group y/i patient monitor recoveri y/i invas group y/i recast therapi recast therapi recast therapi recast therapi group y/i group y/i y/i oper y/i btig estim compani report
preview forecast revenu adj ep in-lin
consensu believ abt earn risk quarter
guidanc tightli control note co guid howev
adjust revenu weaker euro final wed also note y/i
revenu comp much easier provid
favor setup though expect new product momentum continu
buoy perform throughout year feel less near-term
catalyst horizon set name apart data coapt trial
tct septemb could trade opportun frankli dont
strong sens bogey investor seem think trial
posit differ degre posit think
ntm ep estim share valuat appropri reflect risk vs
turn report segment expect continu soft epd due
lag market growth russia expect double-digit growth
wouldnt surpris result come light diagnost
consist strong perform back alin europ aler
within anticip grow contribut ellips mri-saf
confirm ramp neuromod model oper growth
fundament remain strong note brew competit
db diabet though smaller continu
perform well libr sale increas reimburs ou final
vascular expect sequenti improv compani gain
japan reimburs fda approv may xienc sierra stent
segment forecast establish pharma con
nutrit con diagnost con
devic con
call expect commentari new portfolio approv limit
xienc stent advisor hdgrid map cathet diagnost
diabet manag final look updat thought around
model chang adjust report revenu estim
currenc howev model expens off-set leav ep estim
net ep gross bpsadj ebit bpssourc btig estim compani filingsnewold chang
valuat abbott rate neutral share appreci
strong new product launch expect although like
product think upsid investor expect decreas feel
target multipl ntm earn appropri mirror histor
rang last year appli estim yield
enough upsid buy rate btig provid price target
healthcar polici chang currenc fluctuat healthcar fall
favor fda regulatori agenc product delay failur execut
merger synergi
cagrntm johnsonjnjsel fishertmobuy bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap bev/sal
abbott incom statement sale ex oper interest incom incom tax expens net ep methodology/abt share net incom ep incl disc marginsgross expensescog oper expens ep btig estim compani report
abbott segment laboratori y/i laboratori y/i growth laboratori y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth diagnost y/i diagnost y/i growth diagnost y/i growthy/i growth oper adj aleretot y/i y/i growth y/i growth oper adj btig estim
abbott segment devicesrhythm manag y/i manag y/i growth manag y/i growth y/i y/i growth y/i growth failur y/i failur y/i growth failur y/i growth y/i y/i growth y/i growth heart y/i heart y/i growth heart y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth devic y/i devic y/i growth devic y/i growth totaltot report segment us y/i report segment y/i report segment ww y/i btig estim compani adjust stj acquisit optic divestitur
preview model revenu adj ep procedur
growth y/i consensu estim revenu
adj ep in-lin us procedur growth y/i
forecast call system sold quarter consensu estim
system like consensu higher system procedur
share pre-split think investor
want sizeabl beat though alway hard know super bull
med-tech market enough
string outperform investor come expect
beat procedur growth sale ad system
instal base part leas model think strategi
may boost procedur volum result system placement
quarter could help compani exceed consensu sale estim
recent implement japanes reimburs dozen new
procedur may also help boost procedur volum think
like miss key metric revenu procedur growth
system placement share trade ntm ep miss would
like result signific stock sell-off
model call system revenu consensu instrument
revenu consensu servic revenu
may focu isrg oper spend last earn call
manag reiter guidanc y/i growth oper
expens model y/i growth metric expect
compani stay within guid rang though investor may prefer
lower end rang
manag may discuss earli japanes market respons newli
reimburs procedur expect largest center japan eager
adopt new procedur robot wonder reimburs
level par laparoscop surgeri enough stimul widespread
interest similar rate prostat adopt higher
reimburs laparoscop also hope get updat
flexibl robot platform lung biopsi expect file
product year compani build commerci team
platform intend target high-volum lung center first may learn
plan initi launch yet model revenu
flex platform
second quarter secur fda clearanc singl port
system urolog indic sp system slate control
launch expect fairli limit impact revenu
potenti greater upsid beyond look detail
launch plan earli hospit interest sp
topic interest may includ transit direct oper india
recent fda clearanc wrist mm stapler
model chang updat model signific move
euro sinc last quarterli report estim isrg revenu
come europ foreign exchang impact translat
headwind result reduc forward revenu estim slightli
leav forecast unchang off-set impact ep
allow three cent impact model
revenu adjust ep revenu
adj ep revenu adj ep
valuat rate neutral continu
out-performance like procedur mayb system trade
ntm ep well almost med tech btig provid price
target neutral-r stock risk includ system sale procedur
growth buy-sid expect capit spend manipul futur
revenu incom adjust btig estim compani filingsnewold changentm inc ingnnot medicalwmginot factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap bev/salescagr
incom etot y/i sale oper interest incom tax non-controlling incom share adjust net adjust adjust net adjust oper expens ep btig estim compani report
enu eda vinci sale rest y/i asp asp realiz inc stock enu y/i vinci instal base da vinci da vinci da vinci da vinci instal y/i seq seq procedur procedures/instal enuetot world-wide y/i y/i singl y/i multisit singl blend report stock enu per stock enu instrument enu y/i enue/procedur inc y/i train enu instal base per train enu y/i enu y/i gross profit product product gross profit servic servic btig estim compani report
procedur eu procedur estim gyn dvh y/i y/i multi y/i singl y/i y/i y/i y/i y/i y/i dvp y/i y/i y/i y/i y/i surgeri includ ent cardiac vascular y/i y/i y/i y/i y/i y/i y/i y/i cardiac y/i y/i multi y/i singl y/i y/i surgeri inc y/i gener y/i y/i world-wide y/i seq btig estim compani report
procedur eou procedur estim y/i eu y/i y/i gastric y/i y/i eu y/i y/i y/i world-wide y/i seq btig estim compani report
buy pt
preview forecast revenu adj ep bit
weaker consensu revenu in-lin ep face easier y/i
comp vs feel compani need post
growth higher move stock quarter alon consid
upcom catalyst expect return lotu biggest driver
upsid rais pt rather move neutral base
read physician europcr think like howev
expect announc call updat tct
septemb might like lotu asid expect share
outperform vs peer cours year ramp high-
growth platform within neuromod wavewrit vercis icd
emblem s-icd reson diagnost steadi cadenc new product
introduct eluvia de next-gen db ep cathet
eas comparison back half expect free cash flow close
also expect remain activ front ad extra
cushion number increas pt reflect
market multipl view lotu may get relaunch drive
investor excit also still investor feel
rate could still make bid compani even
say discuss
respect procedur base commentari physicians/provid
seem core procedur stabl though sequenti
aftermath strong flu season anticip continu out-performance
med-surg buoy new product introduct neuromod urolog
step-up expect continu momentum back half post
launch advanc seal obtain reimburs franc within
tradit icd continu benefit emblem s-icd
replac cycl tailwind flip side remain conserv pacer
given tough y/i comp also expect continu share shift away de
segment competit trial
call look forward commentari recent includ
cryterion medic privat light intra-quart specul
bid manag may address whether compani open
sell either way wouldnt surpris extra investor
scrutini commentari future/long-term plan possibl
question given movement litig
earli juli manag might comment expect
specif product line model ww sale con
ww cv sale con ww endoscopi sale con
ww urolog sale con ww neuromod sale
con
model chang adjust report revenu estim
weaker euro howev model expens off-set leav ep
valuat rate buy price target base
month ep estim multipl mirror current next
twelv month multipl feel appropri given current trade
multipl bsx peer differenti portfolio risk includ soft
emerg market competit slippag product timelin chang
procedur risk tavr reimburs futur devic data
fda use cash/m possibl multipl contract
oper net incom adj oper incom btig estim compani filingsnewold changentm johnsonjnjsel bdxnot scientificbuy factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap
boston scientif incom enet y/i product gross research adjust oper incom one-tim interest pre-tax provis incom tax adjust net adjust ep share net oper pre-tax net product product product product tax tax growth adjust adjust pre-tax pre-tax adjust incom tax adjust net adjust tax btig estim compani report
boston scientif revenu edrug-elut y/i y/i heart y/i y/i y/i y/i y/i y/i y/i y/i y/i pelvic y/i y/i btig estim compani report neuromodul reclassifi segment electrophysiolog form rhythm neuro segment begin
preview model revenu ep vs consensu
estim note guidanc provid late april
revenu ep model ww thv
sale thv thv lower consensu
forecast thv thv quarter remain
imposs predict havent seen intra-quart sign point
either direct given ew run sinc result weaker tavr
result think investor want thv least hit consensu
think recent trend low volum center growth ramp
sapien japan sustain addit ew face easier
y/i comp vs also wonder
slower procedur growth price sensit europ
evid ew number last quarter non-tavr busi believ
upsid possibl surgic valv segment intuiti elit
momentum roll-out inspiri resilia valv
beyond quarterli result expect investor focu timelin name
resumpt centera launch europ fda approv ultra
late heel europcr also monitor cardioband sale recal
cardioband revenu less understand edward
continu point easier less time-consum procedur said
wonder risk meet tmtt guidanc full
year final anticip discuss recent initi nation
coverag analysi nca tavr though realist manag may
comment beyond state press releas final expect
commentari around competit dynam europ
model chang adjust report revenu estim
weaker euro howev model expens off-set leav ep
estim unchang model adjust debt
refinanc announc earli june yet learn
averag interest rate debt retir
valuat edward rate neutral feel ew current market
capit price lead market share matur tavr market
year feel share fairli valu btig provid
price target neutral-r stock risk includ competit patent
litig slippag product timelin chang procedur
reimburs futur devic data fda possibl multipl
newnewold incom ep growth btig research estim compani file
ntm johnsonjnjsel bdxnot scientificbsxbuy lifesciencesewneutr factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/salescagr
edward incom revenu inc thv return y/i good gross sg other- total oper oper incom ex interest interest expens pre-tax incom tax non-gaap net non-gaap share ex marginsgross net total total total oper tax ep btig estim compani report
edward gaap revenu us y/i ou y/i heart y/i heart y/i y/i gaap net y/i non-gaap revenu us y/i ou y/i heart y/i heart y/i y/i non-gaap net y/i btig estim compani report
preview model revenu ep vs
consensu estim ep rang ep estim
rather wide forecast rang
outlier sure differ came given
guid oper margin estim may
incorpor excess tax benefit earli year note exclud tax
benefit manag estim tax rate model
think investor extract outlier exceed
may anyway strong revenu share could see pressur
given lofti valuat
estim reflect stabl procedur modest sequenti
uptick sale forc typic undergo annual train
schedul vacat soften ou estim weaker
euro though could prove conserv result mimic similar size
uptick seen prior quarter given share run sinc result
sens investor want sizabl beat stock continu
climb view swing factor ramp japan rp
would surpris see stemi dtu feasibl studi complet
enrol earlier expect summer timelin per last updat
earli may alreadi enrol patient
feasibl studi enrol occur earlier expect would
curiou see might posit present outcom
tct anticip manag provid updat ramp
germani impella post ce mark approv
model chang adjust report revenu estim
weaker euro howev model expens off-set leav ep
valuat rate neutral feel compani above-
averag revenu growth gross margin warrant premium multipl
peer share ntm revenu estim fewer near-
term catalyst move materi higher near-term think
share risk-reward roughli equal btig provid price target
neutral-r stock risk includ reimburs slippag product
timelin chang procedur patent litig futur devic data
fda possibl multipl expans
impella sale impella sale net incom btig estim compani filingsnewold chang
ntm inc ingnnot factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/salescagr
abiom incom product fund total y/i good gross sg amort intangibles- total oper incom loss invest incom incom incom expens pre-tax incom incom gaap net incom gaap share non-gaap non-gaap non-gaap ex select calendar loss net product product product oper ep btig estim compani report
abiom revenu commercialnew impella unit asp stock impella cp cp unit cp asp cp stock impella unit asp stock impella rp rp unit rp asp rp stock stock y/i consol instal rate new growth impella y/i inventori inventori impella impella product trial impella impella product product y/i product btig estim compani report
preview fiscal third quarter forecast revenu
adjust ep consensu
estim includ diagnost consensu
breast health con medic aesthet con
gyn surgic con skelet health con
outlook mostli in-lin consensu weve set see
achiev estim cyno medic aesthet busi given
heighten scrutini divis sale perform last
quarter miss reset guidanc expect aesthet turnaround
take time slightli concern consensu expect
well previou consensu estim may still littl
high although aesthet contribut sale investor
made top prioriti share miss howev small would like
pressur share recent ralli share potenti miss cyno
holx largest divis expect continu solid perform
diagnost breast health manag may discuss recent ou
regulatori approv new assay within diagnost busi gyn
surgic sale model growth quarter sinc expect novasur
weak off-set robust growth myosur
trade ntm price-to-earnings multipl well ntm price-to-earnings
averag multipl mid-cap comp group expect holx multipl
increas time compani get aesthet gyn surgic
divis back track maintain perform core breast
diagnost segment
model chang updat model signific move
euro sinc last quarterli report approxim holx
revenu come europ foreign exchang impact translat
headwind result reduc forward revenu estim slightli
leav forecast unchang off-set impact ep
model revenu adj ep
revenu adj ep revenu adj
revenu incom btig estim compani filingsnewold chang
valuat rate buy pt base
month adjust ep estim use multipl comp group
reflect compani slightli lower revenu growth investor sentiment
unlik turn time risk includ cyno result
adopt chang reimburs diagnost price
slowdown novasur competit success integr cyno
ntm entm eepsrevsdentsplyxraynot factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap bev/salescagr
holog incom million except total y/i sell gener oper interest incom incom tax incom share net calendar loss oper btig estim compani report
holog revenu million except selenia dffm asp y/i selenia tomo asp y/i tomo instal y/i breast imag revenu system y/i breast imag y/i imag y/i breast y/i y/i breast y/i breast revenu y/i breast revenu y/i y/i y/i y/i diagnost y/i y/i y/i y/i gyn surgic y/i skelet y/i y/i y/i y/i aesthet revenu y/i y/i revenu y/i btig estim compani report
preview varian fiscal third quarter forecast gross oncolog order
y/i consensuss estim y/i
order like most-watch metric lumpi quarter
quarter command premium price-to-earnings multipl large-cap
med-tech compani think compani need report gross order
result least line consensu keep share current level
model revenu y/i vs consensu
y/i non-gaap ep forecast vs street
model proton revenu especi lumpi revenu
proton mean differ sale beat miss
sirtex srx-asx rate acquisit tabl hope get
updat manag var outlook and/or return cash
sharehold though long histori share buyback believ
investor would cheer strategi includ ad anoth
oncology-rel pillar strengthen var domin posit radiat
area focu var earn call may includ overal growth rate
linear acceler market thought impact tariff halcyon
adopt recent acquisit compani taiwanes distributor
model chang updat model signific move
euro sinc last quarterli report though proport revenu
come emea region fluctuat quarter quarter estim
total revenu would impact euro shift foreign
exchang impact translat headwind overal sale result
reduc forward estim revenu oncolog gross order
slightli leav forecast unchang off-set impact ep
allow two cent impact model
revenu non-gaap ep
revenu non-gaap ep revenu
valuat varian rate neutral feel current valuat
ntm ep estim fair expens varian premium multipl
compani similar growth btig assign price target
neutral-r stock risk includ halcyon adopt chang oper
margin capit spend slow hospit govern new
competit healthcar multipl gener trade lumpi quarterli
gross incom ebit btig estim compani filingsnewold chang
ntm johnsonjnjsel bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap
varian incom oncolog total y/i good gross sg one-tim total oper incom loss invest incom pre-tax incom incom non- net incom continu net earn discontinu non- dilut share net ex select calendar loss net product product product oper ep ep btig estim compani report
varian revenu eoncolog gross america y/i net america order y/i gross emea y/i net emea order y/i gross apac order y/i net apac y/i gross y/i net order y/i trail month gross trail month net y/i contract y/i oncolog y/i gross y/i y/i y/i gross y/i y/i y/i btig estim compani report
preview think may report strong result second quarter
forecast sale non-gaap loss per share
vs consensuss estim non-gaap lp sale
estim reflect y/i growth quarter lower y/i growth
y/i growth seen price come strong
think launch seemingli littl pressur libr far
think beat estim share move higher
seem enjoy strong patient adopt first quarter rise
tide abbott libr launch lift cgm boat think trend
may hold anoth coupl quarter worri price
beyond feel share may move higher first
initi concern price pressur face competit
disappear expect enjoy quarter increas
patient volum without off-set price launch new no-
calibr system think insur may increas payment level
slightli libr may yet factor contract
sale guidanc year rais last quarter model
consensu put beat expect
would expect annual guidanc nudg higher
beyond libr price investor may focus dxcm product
pipelin collabor verili type ii offer roll-out
medicar popul new cgm entrant
despit anticip beat rais next coupl quarter
invest horizon therefor remain neutral
model chang make chang model
valuat rate neutral believ current multipl
estim ntm ev/sal expens given potenti slow
growth seem support investor feel share trade
quarterli beat miss concern competit
price like immedi and/or increas spend told
expect exceed revenu estim wonder happen
price late like risk includ competit increas
spend chang revenu growth rate fda product recal
reimburs price pressur
ntm inc ingnnot sciencesexasbuy medicalwmginot factset data btig estimatespr profitev/salescagrcompanytickerr ptpricemarket cap
incom product develop grant oper expens tax expens net incom share net incom net incom analysisgross profit net incom revenu oper oper btig estim compani report
revenu eworldwid patient basebegin new drop patient re-ord disclos histor patient price revenu re-ord disclos histor patient price revenu hardwar revenu sensor kit order per quarter disclos histor per sensor revenu product btig estim compani report
preview forecast revenu lp in-lin
consensu model complet cologuard test consensu
estim within guidanc beat estim
would surpris us given compani histori midpoint
guidanc impli step-up sequenti seem conserv vs
histor trend aberr given flu neg impact
consid enhanc market pr effort cologuard
shield plan sign interpret manag bullish
tone recent investor confer think strong chanc
volum beat share continu ralli
call expect focu pathway expand cologuard label
patient young anticip updat earli impact
recent market effort new televis ad air june
also look increment discuss develop effort toward liver
lung cours one long-term initi garner plenti attent
penetr hospit system thu would expect discuss
outreach effort improv electron order final follow
compani recent convert offer june use cash proce
need cash like area heighten focu
model chang updat model june convert
offer revenu estim unchang
valuat rate buy pt base dcf
risk includ cologuard adopt unsuccess expans younger
patient increas spend competit data new product guidelin
chang chang discuss chang obamacar chang
reimburs addit delay poor data lung test
need capit difficulti hire salespeopl creat strong
advertis high-multipl healthcar stock fall favor
revenu growth test growth incom ep expens btig estim compani filingsnewold chang
exact scienc incom million usd except per-shar research gener sale interest expens incom incom incom ep share analysi revenu good net incom tax incom net incom btig estim compani report
exact scienc revenu million enumb order sequenti new physician adopt assumptionsnew physician order tests/new complianc test new reorder rate assumptionsreord order tests/reord complianc test reorder cologuard test growth tests/ord testsscreen opportun penetr rate annual volum tradit volum medicar volum volum tradit medicar reimburs reimburs medicar reimburs medicar laboratori servic accrual revenu revenue-per-test ex- btig estim compani report
preview second quarter forecast revenu
non-gaap lp vs consensu estim non-
gaap lp estim top end guidanc rang
quarter recent quarter expect exceed
consensu expect addit increas awar
demand think patient access tailwind help boost omnipod
adopt includ medicar part formulari coverag unitedhealthcar
rate in-network coverag note rack nice win
earlier month design prefer insulin pump british
columbia patient access win extend compani high growth
rate unclear us share sold recent think beat could
push higher
model us omnipod sale intern omnipod
sale compani quarterli guidanc rang case
drug deliveri revenu midpoint guidanc rang
model gross margin quarter think room upsid
metric manag remain focus cut cost model
gross margin switch direct sale europ lift
margin back half year
full year guid total revenu model
total revenu includ us omnipod sale
intern omnipod sale drug deliveri sale
expect commentari earn call center juli transit
direct sale europ prior manag discuss point solid
prepar put salesforc place sign partnership
distribut service/logist anticip earli day
direct busi model go well although would surpris
inventori channel need work
immedi transit date overal think dedic
salesforc focus omnipod bolster intern sale margin
topic call may includ clinician feedback recent
american diabet associ confer market respons dash
system potenti new pharma partnership drug deliveri
segment progress horizon autom glucos control system
model chang make chang model
valuat insulet rate neutral trade ntm revenu
forecast continu see benefit tubeless insulin pump
omnipod result exceed expect believ stock
fairli valu time btig provid price target neutral-r
stock risk includ disrupt intern revenu instal
patient base increas competit potenti prefer partnership
major insur group lack visibl next drug
deliveri product
ntm inc ingnnot diabetestndmnot medicalwmginot factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap
incom statement adjust nd etot revenu y/i growth adjust neighborhood good oper expens tax expens net incom share net incom adjustments- gaap net incom gaap ep growth y/ymarginsgross incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnet incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmexpensescog oper expens quarterli result growth rate adjust neighborhood divestituresourc btig estim compani report
revenu etot revenu omnipod y/i omnipod y/i deliveri y/i revenu exclud neighborhood y/i growth adjust neighborhood revenu omnipod revenu breakdownbegin instal new patient start patient y/i patient attrit instal instal base average es order per re-ord annual new user quarterli annual asp new patient revenu new user total omnipod y/i productivity/rep omnipod revenu breakdownbegin instal new patient patient y/i patient attrit instal instal base average es order per re-ord quarterli annual asp new user quarterli annual asp new patient new user total omnipod y/i deliveri revenuesymphoni health data forecast neulasta syring neulsasta onpro total neulasta y/i estim neulasta sale attribut onpro neulasta sale attribut onpro total neulasta onpro end-us neulasta onpro impli neulasta onpro total neulasta onpro total neulasta onpro revenu total neulasta onpro drug total report drug deliveri sourc btig estim compani report symphoni health solut symphoni health symphoni health b/c btig estim report drug deliveri revenu /f btig estim
preview forecast revenu ep vs consensu
total revenu estim includ rainbow
sale consensu model exclud royalti project
y/i growth product revenu quarter consensu
expect y/i growth
exceed consensu expect sever quarter
think trend like continu rainbow compani newer
technolog offer like sedlin nomolin grew rapidli
first quarter expect growth sustain along strength
core busi push result past intern consensu
expect think beat mayb rais like expect beat
harder predict rais seem want set guidanc
level meet surpass
guidanc full year set total revenu product
revenu ep model slightli
total revenu product revenu y/i growth
revenu y/i growth ep
think much revenu boost philip phg rate co-
market agreement ahead integr rainbow
phg monitor complet take time sell offer
hospit addit technolog still slate integr
anticip phg-relat revenu may start bigger impact
result
beyond phg relationship think investor focus potenti
meaning new product emerg masi intern effort
back half year next year also expect manag discuss
recent clinic studi win monitor technolog includ
adopt unit arab emir nation screen critic
congenit heart diseas newborn
model chang make chang model
valuat rate buy price target base
mo ep forecast believ compani strong growth profil
philip partnership fast cadenc product innov warrant valuat
multipl comp group compar compani fast-
grow product revenu note optic masi total revenu growth
rate impact royalti roll later year view
reason comp tabl includ profit med-tech compani
similar revenu ep growth rate risk includ price hospit
admiss volum hb adopt margin advers impact relationship
philip competit
ntm medicalgmedneutr factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/sal
masimo incom eproduct y/i y/i y/i good gross litig award defens costs- total oper oper incom non-oper pre-tax incom tax non-control interest net share total non- adjustments- non- net adjust ep marginsgross gross net total total total oper ep ep ep ex royalti btig estim compani file adj ep includ adjust due fx
masimo revenu eglob instal base instal base new unit y/i unit annual retir instal base y/i new unit rainbow monitor total instal busi averag instal base averag y/i sensor asp estimate sensor respiratori set y/i total product busi asp y/i rainbow y/i rainbow average rb instal base average y/i rainbow sensor asp estimate sensor y/i total product sphb y/i product y/i y/i net y/i btig estim compani report
preview model revenu adj ep similar
consensu estim euro basket emerg market
currenc larg off-set result modestli neg impact
fx estim model constant currenc growth includ
tandem vs manag full year expect see
littl risk total top-lin forecast share sizabl run
especi announc plan reconsid coverag vn
treatment-rel depress think bar pretti high current
share price share move higher investor like
expect clean revenu beat upsid import neuromod
segment neuromod hard predict last quarter manag said
refus discount custom like come back
quarter compani could refus discount push sale
next quarter
cardiopulmonari hlm sale continu benefit upgrad
replac exist devic competit gain turn
heart valv manag continu point aggress expans
percev grow doubl digit remain rel cautiou
around percev competit posit seem still low bar
howev expect anoth quarter pressur segment
result chang oem contract regard neuromod anticip
on-going sentiva adopt howev revenu growth
weaker expect later learn co chose walk
away unprofit contract y/i comparison demand
thu cautiou around improv recent
receipt ce mark sentiva buoy ou momentum howev
compani previous note take measur approach roll-out
estim segment model cardiopulmonari sale con
heart valv sale con neuromod sale
call anticip enrol updat prelud trial
caisson europcr may manag note perform trans-
septal procedur also indic plan resum feasibl work shortli
thereaft expect discuss long-term initi includ heart
failur hf treatment-resist depress updat restore-lif trial
sleep apnea use cash also interest think could
discuss potenti outcom regard medicar coverag vn
impact might final await updat statu
imthera trial paus close enrol complet
model chang make modest chang revenu model base
updat fx movement quarter
valuat rate neutral price-to-earnings basi share trade
mani livn peer large-cap mid-cap grow revenu similar
place said share trade mid cap name feel grow
faster long term use target multipl split differ
would see hypothet price target close shade
trade today think immedi accret growth market
could serv catalyst stock feel quit bit good news
price depress say could big
disappoint btig provid price target neutral-r stock
slow vn new patient growth competit issu fda leadership
transit capit deploy new product trials/develop
unsuccess bid medicar coverag vn treatment-resist
growth btig estim compani filingsnewold changentm capjohnson johnsonjnjsel bdxnot scientificbsxbuy cap capresmedrmdnot medicalwmginot cap factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/salescagr
non-gaap incom good sold oper incom continu incom continu minor tax expens net share oper pre-tax net net net net oper calcul effect tax calcul effect tax btig estim compani reportsfor quarter tax-effect earn use tax rate deriv ep comparison purpos
consolid million machin includ report cc report cc system report cc report cc report cc heart report cc heart valv includ sutureless report cc report cc cc sorin btig estim compani note sub-seg within cardiopulmonari heart valv cardiac rhythm repres btig estim actual result attempt estim line item base histor provid sorin prior merger go-forward basi compani disclosur
